Article Text

Download PDFPDF
Concurrent primaries of vaginal clear cell adenocarcinoma and endometrial adenocarcinoma in a 39-year old woman with in utero diethylstilbestrol exposure
  1. C. Keller1,
  2. R. Nanda1,
  3. R. L. Shannon2,
  4. A. Amit1 and
  5. A. L. Kaplan1
  1. 1Department of Obstetrics and Gynecology and
  2. 2Department of Pathology, Baylor College of Medicine, Houston, Texas
  1. Current address and address correspondence and reprint requests to: Amnon Amit, MD, Department of Obstetric Gynecology, Gyn-Onc Division, Rambam Medical Center, POB 9602, Haifa, Israel, 31096. E-mail: amnonamit{at}


Diethylstilbestrol (DES) was used widely in the late 1940s in an attempt to prevent adverse pregnancy outcomes. In 1971 the US Food and Drug Administration proscribed its use for pregnancy support secondary to its association with clear cell adenocarcinoma of the vagina. Several studies in animal models demonstrated an association with endometrial cancer among offspring following in utero DES exposure. To date, there is only one case report of endometrial cancer in women exposed to DES in utero. We present the first case, to our knowledge, of a woman exposed to DES in utero who presented with double primaries of clear cell cancer of the vagina concomitant with endometrial cancer.

  • clear cell cancer of the vagina
  • diethylstilbestrol
  • endometrial neoplasms

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.